Rossari Biotech declared a dividend of Re. 0.50 per equity share for the financial year ended March 31, 2026, at its 17th Annual General Meeting (AGM) held on July 20, 2026. The meeting, conducted via video conferencing, saw the approval of all eight resolutions listed in the agenda, including the adoption of standalone and consolidated financial statements and the appointment of key directors.

The dividend will be credited to members holding shares on the record date within 10 working days from the conclusion of the AGM. Shareholders approved the adoption of the audited standalone and consolidated financial statements for the financial year ended March 31, 2026, along with the reports of the Board of Directors and Auditors.

Key Appointments and Approvals

The AGM approved the appointment of Mr. Udeypaul Singh Gill (DIN: 00004340) and the re-appointment of Ms. Esha Padmanabhan Achan (DIN: 10350369) as Non-Executive, Independent Directors of the company. Mr. Edward Menezes (DIN: 00149205) was appointed as a director liable to retire by rotation. Additionally, members ratified the remuneration payable to M/s. R. Shetty & Associates, Cost Auditors of the company.

A resolution regarding material related party transactions with Unitop Chemicals Private Limited was also passed. In accordance with SEBI regulations, the Promoter & Promoter Group did not vote on this resolution.

Voting Results

The voting results, scrutinized by M/s. Shah Patel & Associates, indicated strong shareholder support for all resolutions. The table below summarizes the voting outcomes for key resolutions:

The remote e-voting facility was available from July 17, 2026, to July 19, 2026. A total of 89,110 shareholders were on record as of the cut-off date of July 13, 2026. The meeting concluded at 12:08 P.M. on July 20, 2026.

Rossari Biotech has highlighted that the agriculture sector is currently facing challenges stemming from the El Niño weather phenomenon, according to a statement reported by CNBC TV18. The company indicated that these climatic conditions are creating headwinds for its agricultural business segment.

Global Uncertainty Clouds Financial Visibility

Adding to the concern over El Niño-related disruptions, Rossari Biotech noted that it is hard to predict revenue and profit growth due to prevailing global uncertainty. The combination of weather-related agricultural stress and broader macroeconomic unpredictability presents a complex operating environment for the company.

Key Concerns at a Glance

The management's commentary underscores the dual pressures of climate-driven demand disruption in agriculture and a challenging global macroeconomic backdrop. Rossari Biotech's remarks reflect a cautious stance on near-term business performance, as reported by CNBC TV18.